NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free MEDP Stock Alerts $404.15 +0.88 (+0.22%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$401.76▼$407.1450-Day Range$291.58▼$413.3152-Week Range$181.50▼$419.42Volume197,391 shsAverage Volume260,472 shsMarket Capitalization$12.43 billionP/E Ratio45.51Dividend YieldN/APrice Target$382.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside5.5% Downside$382.00 Price TargetShort InterestHealthy3.89% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.97Based on 11 Articles This WeekInsider TradingSelling Shares$76.65 M Sold Last QuarterProj. Earnings Growth20.89%From $10.53 to $12.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector70th out of 938 stocksCommercial Physical Research Industry3rd out of 10 stocks 1.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $382.00, Medpace has a forecasted downside of 5.5% from its current price of $404.15.Amount of Analyst CoverageMedpace has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.89% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 2.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 3.3 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Medpace this week, compared to 6 articles on an average week.Search InterestOnly 8 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows16 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,651,647.00 in company stock.Percentage Held by Insiders25.70% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 20.89% in the coming year, from $10.53 to $12.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 45.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 45.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 241.39.Price to Earnings Growth RatioMedpace has a PEG Ratio of 2.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 22.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesMarch 20, 2024 | insidertrades.comInsider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) VP Sells 102 Shares of StockMarch 19, 2024 | insidertrades.comMedpace Holdings, Inc. (NASDAQ:MEDP) Director Sells $102,467.50 in StockMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 11, 2024 | insidertrades.comInsider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells 25,000 Shares of StockMarch 28, 2024 | businesswire.comMedpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024March 28, 2024 | businesswire.comMedpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024March 28, 2024 | msn.comAlara is Madisonville's newest American restaurant, latest from popular restaurant groupMarch 27, 2024 | msn.comNew restaurant opens in Cincinnati's Madisonville neighborhoodMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 25, 2024 | bizjournals.comLooking Glass Hospitality announces menu, hours for new $6.5M upscale restaurant, AlaraMarch 23, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Rating Lowered to Hold at StockNews.comMarch 22, 2024 | finance.yahoo.comShould You Invest in Medpace (MEDP)?March 22, 2024 | finance.yahoo.comInvestors in Medpace Holdings (NASDAQ:MEDP) have seen enviable returns of 609% over the past five yearsMarch 21, 2024 | americanbankingnews.comBrokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Price Target at $377.67March 19, 2024 | finance.yahoo.comDoes Medpace Holdings (MEDP) Have The Potential to Maintain Strong Growth?March 19, 2024 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Director Ashley M. Keating Sells 250 SharesMarch 19, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Now Covered by Analysts at Deutsche Bank AktiengesellschaftMarch 18, 2024 | insidermonkey.comInsiders Are Selling These 5 Stocks in 2024March 17, 2024 | bizjournals.comConvergence of factors powers the innovative ecosystem’s competitive advantage in OhioMarch 16, 2024 | finance.yahoo.comMEDP Apr 2024 580.000 callMarch 15, 2024 | bizjournals.comFive things to know, and Cincinnati chili in the Windy City? I'm a skepticMarch 14, 2024 | bizjournals.comLooking Glass Hospitality announces opening date, menu for newest restaurant venture, AlaraMarch 12, 2024 | uk.finance.yahoo.comPatient Recruitment and Retention Services Global Market Report 2024March 11, 2024 | seekingalpha.comMedpace: Exceptional Performance, Almost Fully Priced InMarch 8, 2024 | markets.businessinsider.comAssessing Medpace Hldgs: Insights From 4 Financial AnalystsMarch 6, 2024 | finance.yahoo.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Medpace Holdings, Inc.'s NASDAQ:MEDP) Stock?March 3, 2024 | ca.finance.yahoo.comMEDP Jun 2024 380.000 callSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today3/29/2024Next Earnings (Estimated)4/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$382.00 High Stock Price Target$452.00 Low Stock Price Target$273.00 Potential Upside/Downside-5.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$8.88 Trailing P/E Ratio45.51 Forward P/E Ratio38.38 P/E Growth2.13Net Income$282.81 million Net Margins15.00% Pretax Margin17.80% Return on Equity63.98% Return on Assets19.02% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual Sales$1.89 billion Price / Sales6.59 Cash Flow$10.11 per share Price / Cash Flow39.97 Book Value$18.22 per share Price / Book22.18Miscellaneous Outstanding Shares30,760,000Free Float22,854,000Market Cap$12.43 billion OptionableOptionable Beta1.38 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.68MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $876.92kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $636.58kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $826.17kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsIncyteNASDAQ:INCYCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELLaboratory Co. of AmericaNYSE:LHView All CompetitorsInsiders & InstitutionsQuadrature Capital LtdSold 20,669 shares on 3/25/2024Ownership: 0.045%PNC Financial Services Group Inc.Bought 488 shares on 3/22/2024Ownership: 0.028%Susan E BurwigSold 102 sharesTotal: $41,106.00 ($403.00/share)Ashley M KeatingSold 250 sharesTotal: $102,467.50 ($409.87/share)Vanguard Group Inc.Bought 142,591 shares on 3/11/2024Ownership: 8.311%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medpace stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price target for 2024? 4 Wall Street research analysts have issued 1 year price objectives for Medpace's shares. Their MEDP share price targets range from $273.00 to $452.00. On average, they expect the company's share price to reach $382.00 in the next year. This suggests that the stock has a possible downside of 5.5%. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2024? Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP stock has increased by 31.8% and is now trading at $404.15. View the best growth stocks for 2024 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings results on Monday, February, 12th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.22 by $0.24. The company had revenue of $498.40 million for the quarter, compared to analysts' expectations of $498.72 million. Medpace had a net margin of 15.00% and a trailing twelve-month return on equity of 63.98%. The business's quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.12 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap Quality ETF (XMHQ), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Medpace issued on next quarter's earnings? Medpace updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 10.180-10.870 for the period, compared to the consensus estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.33%), Vanguard Group Inc. (8.31%), Wasatch Advisors LP (3.87%), Riverbridge Partners LLC (2.23%), Riverbridge Partners LLC (2.13%) and Boston Trust Walden Corp (1.59%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEDP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.